Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Eur J Pharm Biopharm. 2022 Aug;177:157-174. doi: 10.1016/j.ejpb.2022.06.014. Epub 2022 Jul 3.
Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized carriers, biocompatibility and idiopathic reactions which could be difficult to predict in the patient. Biomimetic approach, a novel step towards personalized medicine bridges these drawbacks by employing endogenous cell membranes to traverse physiological barriers. Camouflaged carriers coated with natural cell membranes possess unique characteristics such as high circulatory periods, and the absence of allogenic and xenogenic responses. Proteins residing on the cell membranes render a diverse range of utilities to the coated nanoparticles including natural efficiency to identify cellular targets, homologous targeting, reticuloendothelial system evasion, biocompatibility and reduced adverse and idiopathic effects. In the present article, we have focused on cell membrane camouflaged nanocarriers for melanoma management. We have discussed various types of biomimetic systems, their processing and coating approaches, and their characterization. We have also enumerated novel avenues in melanoma treatment and the combination of biomimetic systems with smart nanoparticulate systems with the potential to bring breakthroughs in the near future. Additionally, immunotherapy-based biomimetic systems to combat melanoma have been highlighted. Hurdles towards clinical translation and ways to overcome them have been explained in detail.
黑色素瘤是一种存在于皮肤基底层的黑素细胞癌。纳米医学为我们提供了管理这种致命肿瘤疾病的有效平台。然而,它也存在许多缺陷,如表面功能化载体的快速清除和调理作用、生物相容性和特发性反应,这些在患者中可能难以预测。仿生方法是迈向个性化医学的新一步,通过利用内源性细胞膜来穿越生理屏障,克服了这些缺陷。用天然细胞膜包被的伪装载体具有独特的特性,如高循环期,以及不存在同种异体和异种反应。细胞膜上的蛋白质赋予涂层纳米颗粒多种用途,包括天然识别细胞靶标、同源靶向、网状内皮系统逃避、生物相容性和减少不良反应和特发性反应的能力。在本文中,我们重点介绍了用于黑色素瘤管理的细胞膜伪装纳米载体。我们讨论了各种类型的仿生系统、它们的处理和涂层方法,以及它们的特性。我们还列举了在黑色素瘤治疗方面的新途径,以及仿生系统与智能纳米颗粒系统的结合,有望在不久的将来带来突破。此外,还强调了基于免疫疗法的仿生系统来对抗黑色素瘤。详细解释了向临床转化的障碍以及克服这些障碍的方法。
Eur J Pharm Biopharm. 2022-8
Anticancer Agents Med Chem. 2022
Clin Transl Med. 2021-2
J Control Release. 2015-12-28
J Control Release. 2021-1-10
Cancer Pathog Ther. 2024-1-12